English
Segment disclosures
Company overviewNIAGEN BIOSCIENCE, INC.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Operating Segments · Analytical Reference Standards And Services Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 423000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 423000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 772000 | USD | 20251104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 2382000 | USD | 20251104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 799000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 1610000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 811000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 784000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 2289000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 791000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 1505000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 714000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 671000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 2198000 | USD | 20241031 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 728000 | USD | 20230809 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1527000 | USD | 20230809 | Open filing evidence |
Operating Segments · Consumer Products Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 24162000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 46575000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 22413000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 26017000 | USD | 20251104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 70217000 | USD | 20251104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 22699000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 44200000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 21501000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 18123000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 54121000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 18647000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 35998000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 17351000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 17400000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 51924000 | USD | 20241031 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 16891000 | USD | 20240807 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 34524000 | USD | 20240807 | Open filing evidence |
Operating Segments · Ingredients Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 5387000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 13951000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 8564000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 7197000 | USD | 20251104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 22985000 | USD | 20251104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 7619000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 15788000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 8169000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 6673000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 14062000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 3301000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 7389000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 4088000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 1424000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 8252000 | USD | 20241031 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 2704000 | USD | 20230809 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 6828000 | USD | 20230809 | Open filing evidence |
Operating Segments · Pharmaceuticals Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:PharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
Operating Segments · Analytical Reference Standards And Services Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 3076000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 3011000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2905000 | USD | 20250304 | Open filing evidence |
Operating Segments · Consumer Products Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 97672000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 76772000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 69528000 | USD | 20250304 | Open filing evidence |
Operating Segments · Ingredients Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 28675000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 19814000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 11137000 | USD | 20250304 | Open filing evidence |
Operating Segments · Pharmaceuticals Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:PharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
Analytical Reference Standards And Services Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 423000 | USD | 20261104 | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 423000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 423000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 772000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 2382000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 799000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 1610000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 811000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 784000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 2289000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 791000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 1505000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 714000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 671000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 2198000 | USD | 20241031 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 728000 | USD | 20240807 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1527000 | USD | 20240807 | Open filing evidence |
Analytical Reference Standards And Services Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 423000 | USD | 20261104 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 772000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 2382000 | USD | 20261104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 791000 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 1505000 | USD | 20240807 | Open filing evidence |
Analytical Reference Standards And Services Segment · Consulting And Other
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ConsultingAndOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 12000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 15000 | USD | 20251104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 55000 | USD | 20251104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 27000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 40000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 13000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 25000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 94000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 36000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 69000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 33000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 17000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 76000 | USD | 20241031 | Open filing evidence |
Analytical Reference Standards And Services Segment · Food Grade NIAGEN
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Analytical Reference Standards And Services Segment · NIAGEN Ingredient
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 0 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20240807 | Open filing evidence |
Analytical Reference Standards And Services Segment · NIAGEN Related
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Analytical Reference Standards And Services Segment · Other Goods And Services
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 423000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 423000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 772000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 2382000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 799000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 1610000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 811000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 784000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 2289000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 791000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 1505000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 714000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 671000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 2198000 | USD | 20241031 | Open filing evidence |
Analytical Reference Standards And Services Segment · Other Ingredients
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Analytical Reference Standards And Services Segment · Pharmaceutical Grade NIAGEN
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Analytical Reference Standards And Services Segment · Reference Standards
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 411000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 411000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 757000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 2327000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 772000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 1570000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 798000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 759000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 2195000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 755000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 1436000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 681000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 654000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 2122000 | USD | 20241031 | Open filing evidence |
Analytical Reference Standards And Services Segment · Services And Other
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 12000 | USD | 20261104 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 15000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 55000 | USD | 20261104 | Open filing evidence |
Analytical Reference Standards And Services Segment · TRUNIAGEN Consumer Product
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Consumer Products Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 23320000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 69895000 | USD | 20261104 | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 24162000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 46575000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 22413000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 26017000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 70217000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 22699000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 44200000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 21501000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 18123000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 54121000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 18647000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 35998000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 17351000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 17400000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 51924000 | USD | 20241031 | Open filing evidence |
Consumer Products Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 23320000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 69895000 | USD | 20261104 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 26017000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 70217000 | USD | 20261104 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 17400000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 51924000 | USD | 20231108 | Open filing evidence |
Consumer Products Segment · Consulting And Other
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ConsultingAndOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Consumer Products Segment · Food Grade NIAGEN
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Consumer Products Segment · NIAGEN Ingredient
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 0 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20240807 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20231108 | Open filing evidence |
Consumer Products Segment · NIAGEN Related
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 23320000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 69895000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 22413000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 26017000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 70217000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 22699000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 44200000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 21501000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 18123000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 54121000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 18647000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 35998000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 17351000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 17400000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 51924000 | USD | 20241031 | Open filing evidence |
Consumer Products Segment · Other Goods And Services
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Consumer Products Segment · Other Ingredients
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Consumer Products Segment · Pharmaceutical Grade NIAGEN
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Consumer Products Segment · Reference Standards
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Consumer Products Segment · Services And Other
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
Consumer Products Segment · TRUNIAGEN Consumer Product
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 23320000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 69895000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 22413000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 26017000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 70217000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 22699000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 44200000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 21501000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 18123000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 54121000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 18647000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 35998000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 17351000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 17400000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 51924000 | USD | 20241031 | Open filing evidence |
Corporate And Reconciling Items
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 70000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 380000 | USD | 20261104 | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 236000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 310000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 74000 | USD | 20260506 | Open filing evidence |
Corporate And Reconciling Items · Consulting And Other
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:ConsultingAndOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 74000 | USD | 20260506 | Open filing evidence |
Corporate And Reconciling Items · Food Grade NIAGEN
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
Corporate And Reconciling Items · NIAGEN Related
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
Corporate And Reconciling Items · Other Goods And Services
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 70000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 380000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 74000 | USD | 20260506 | Open filing evidence |
Corporate And Reconciling Items · Other Ingredients
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
Corporate And Reconciling Items · Pharmaceutical Grade NIAGEN
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
Corporate And Reconciling Items · Reference Standards
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
Corporate And Reconciling Items · Services And Other
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 70000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 380000 | USD | 20261104 | Open filing evidence |
Corporate And Reconciling Items · TRUNIAGEN Consumer Product
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
Ingredients Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 3802000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 17753000 | USD | 20261104 | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 5387000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 13951000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 8564000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 7197000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 22985000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 7619000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 15788000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 8169000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 6673000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 14062000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 3301000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 7389000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 4088000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 1424000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 8252000 | USD | 20241031 | Open filing evidence |
Ingredients Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 3802000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 17753000 | USD | 20261104 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 7197000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 22985000 | USD | 20261104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 3301000 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 7389000 | USD | 20240807 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 1424000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 8252000 | USD | 20231108 | Open filing evidence |
Ingredients Segment · Consulting And Other
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ConsultingAndOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Ingredients Segment · Food Grade NIAGEN
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 3372000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 15609000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 7309000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 6405000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 19373000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 5994000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 12968000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 6974000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 5760000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 12992000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 3144000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 7232000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 4088000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 1424000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 7822000 | USD | 20241031 | Open filing evidence |
Ingredients Segment · NIAGEN Ingredient
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 3144000 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 7232000 | USD | 20240807 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 1424000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 7822000 | USD | 20231108 | Open filing evidence |
Ingredients Segment · NIAGEN Related
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 3797000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 17309000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 8159000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 6915000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 22273000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 7384000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 15358000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 7974000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 6660000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 13892000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 3144000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 7232000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 4088000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 1424000 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 7822000 | USD | 20241031 | Open filing evidence |
Ingredients Segment · Other Goods And Services
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 5000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 444000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 405000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 282000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 712000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 235000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 430000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 195000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 13000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 170000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 157000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 157000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 430000 | USD | 20241031 | Open filing evidence |
Ingredients Segment · Other Ingredients
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 430000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 405000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 282000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 712000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 235000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 430000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 195000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 13000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 170000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 157000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 157000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 430000 | USD | 20241031 | Open filing evidence |
Ingredients Segment · Pharmaceutical Grade NIAGEN
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 425000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 1700000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 850000 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 510000 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 2900000 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1390000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 2390000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 1000000 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 900000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 900000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Ingredients Segment · Reference Standards
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Ingredients Segment · Services And Other
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 5000 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 14000 | USD | 20261104 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
Ingredients Segment · TRUNIAGEN Consumer Product
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260506 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 0 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241031 | Open filing evidence |
Pharmaceuticals Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdcx:PharmaceuticalsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 0 | USD | 20261104 | Open filing evidence |
Analytical Reference Standards And Services Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 3076000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 3011000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2905000 | USD | 20250304 | Open filing evidence |
Analytical Reference Standards And Services Segment · Consulting And Other
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ConsultingAndOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 73000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 120000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 101000 | USD | 20250304 | Open filing evidence |
Analytical Reference Standards And Services Segment · NIAGEN Ingredient
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Analytical Reference Standards And Services Segment · NIAGEN Related
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENRelatedMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Analytical Reference Standards And Services Segment · Other Goods And Services
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherGoodsAndServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 3076000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 3011000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2905000 | USD | 20250304 | Open filing evidence |
Analytical Reference Standards And Services Segment · Other Ingredients
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Analytical Reference Standards And Services Segment · Pharmaceutical Grade Niagen
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:PharmaceuticalGradeNiagenMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Analytical Reference Standards And Services Segment · Reference Standards
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ReferenceStandardsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 3003000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 2891000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2804000 | USD | 20250304 | Open filing evidence |
Analytical Reference Standards And Services Segment · TRUNIAGEN Consumer Product
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:TRUNIAGENConsumerProductMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Consumer Products Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 97672000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 76772000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 69528000 | USD | 20250304 | Open filing evidence |
Consumer Products Segment · Consulting And Other
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ConsultingAndOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Consumer Products Segment · NIAGEN Ingredient
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Consumer Products Segment · NIAGEN Related
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENRelatedMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 97672000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 76772000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 69528000 | USD | 20250304 | Open filing evidence |
Consumer Products Segment · Other Goods And Services
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherGoodsAndServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Consumer Products Segment · Other Ingredients
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Consumer Products Segment · Pharmaceutical Grade Niagen
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:PharmaceuticalGradeNiagenMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Consumer Products Segment · Reference Standards
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ReferenceStandardsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Consumer Products Segment · TRUNIAGEN Consumer Product
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:TRUNIAGENConsumerProductMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 97672000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 76772000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 69528000 | USD | 20250304 | Open filing evidence |
Ingredients Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 28675000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 19814000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 11137000 | USD | 20250304 | Open filing evidence |
Ingredients Segment · Consulting And Other
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ConsultingAndOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Ingredients Segment · NIAGEN Ingredient
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 24110000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 17540000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 10550000 | USD | 20250304 | Open filing evidence |
Ingredients Segment · NIAGEN Related
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENRelatedMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 27894000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 19240000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 10550000 | USD | 20250304 | Open filing evidence |
Ingredients Segment · Other Goods And Services
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherGoodsAndServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 781000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 574000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 587000 | USD | 20250304 | Open filing evidence |
Ingredients Segment · Other Ingredients
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 781000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 574000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 587000 | USD | 20250304 | Open filing evidence |
Ingredients Segment · Pharmaceutical Grade Niagen
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:PharmaceuticalGradeNiagenMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 3784000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1700000 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Ingredients Segment · Reference Standards
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ReferenceStandardsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Ingredients Segment · TRUNIAGEN Consumer Product
Statement Business Segments · Subsegments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:TRUNIAGENConsumerProductMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260304 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250304 | Open filing evidence |
Food Grade NIAGEN · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
Food Grade NIAGEN · Consumer Products Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
Food Grade NIAGEN · Corporate And Reconciling Items
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
Food Grade NIAGEN · Ingredients Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 4928000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 12237000 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 5994000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 12968000 | USD | 20260804 | Open filing evidence |
NIAGEN Ingredient · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 0 | USD | 20240508 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20231108 | Open filing evidence |
NIAGEN Ingredient · Consumer Products Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 0 | USD | 20240508 | Open filing evidence |
NIAGEN Ingredient · Ingredients Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 4088000 | USD | 20240508 | Open filing evidence |
NIAGEN Related · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20240807 | Open filing evidence |
NIAGEN Related · Consumer Products Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 24162000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 46575000 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 22699000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 44200000 | USD | 20260804 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 18647000 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 35998000 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 17351000 | USD | 20240508 | Open filing evidence |
NIAGEN Related · Corporate And Reconciling Items
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
NIAGEN Related · Ingredients Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 5353000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 13512000 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 7384000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 15358000 | USD | 20260804 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 3144000 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 7232000 | USD | 20240807 | Open filing evidence |
Other Goods And Services · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 423000 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 799000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 1610000 | USD | 20260804 | Open filing evidence |
Other Goods And Services · Consumer Products Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20240508 | Open filing evidence |
Other Goods And Services · Corporate And Reconciling Items
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 236000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 310000 | USD | 20260804 | Open filing evidence |
Other Goods And Services · Ingredients Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 34000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 439000 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 235000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 430000 | USD | 20260804 | Open filing evidence |
Other Ingredients · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20240508 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20231108 | Open filing evidence |
Other Ingredients · Consumer Products Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20240508 | Open filing evidence |
Other Ingredients · Corporate And Reconciling Items
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
Other Ingredients · Ingredients Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 25000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 430000 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 235000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 430000 | USD | 20260804 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 157000 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 157000 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20240508 | Open filing evidence |
Pharmaceutical Grade NIAGEN · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
Pharmaceutical Grade NIAGEN · Consumer Products Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
Pharmaceutical Grade NIAGEN · Corporate And Reconciling Items
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
Pharmaceutical Grade NIAGEN · Ingredients Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 425000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 1275000 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1390000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 2390000 | USD | 20260804 | Open filing evidence |
Reference Standards · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 411000 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 772000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 1570000 | USD | 20260804 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 681000 | USD | 20240508 | Open filing evidence |
Reference Standards · Consumer Products Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 0 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20240508 | Open filing evidence |
Reference Standards · Corporate And Reconciling Items
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
Reference Standards · Ingredients Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 0 | USD | 20240508 | Open filing evidence |
Services And Other · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 12000 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 27000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 40000 | USD | 20260804 | Open filing evidence |
Services And Other · Consumer Products Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
Services And Other · Corporate And Reconciling Items
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 236000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 310000 | USD | 20260804 | Open filing evidence |
Services And Other · Ingredients Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 9000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 9000 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
TRUNIAGEN Consumer Product · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
TRUNIAGEN Consumer Product · Consumer Products Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 24162000 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 46575000 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 22699000 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 44200000 | USD | 20260804 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 18647000 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 35998000 | USD | 20240807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 17351000 | USD | 20240508 | Open filing evidence |
TRUNIAGEN Consumer Product · Corporate And Reconciling Items
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
TRUNIAGEN Consumer Product · Ingredients Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260804 | Open filing evidence |
Consulting And Other · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdxc:ConsultingAndOtherMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 101000 | USD | 20240306 | Open filing evidence |
NIAGEN Ingredient · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 0 | USD | 20240306 | Open filing evidence |
NIAGEN Ingredient · Consumer Products Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 0 | USD | 20240306 | Open filing evidence |
NIAGEN Ingredient · Ingredients Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 10550000 | USD | 20240306 | Open filing evidence |
NIAGEN Related · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdxc:NIAGENRelatedMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 0 | USD | 20240306 | Open filing evidence |
Other Goods And Services · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdxc:OtherGoodsAndServicesMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 2905000 | USD | 20240306 | Open filing evidence |
Other Ingredients · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 0 | USD | 20240306 | Open filing evidence |
Other Ingredients · Consumer Products Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 0 | USD | 20240306 | Open filing evidence |
Other Ingredients · Ingredients Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 587000 | USD | 20240306 | Open filing evidence |
Reference Standards · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdxc:ReferenceStandardsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 2804000 | USD | 20240306 | Open filing evidence |
TRUNIAGEN Consumer Product · Analytical Reference Standards And Services Segment
Subsegments · Statement Business Segments
Source dimensions
us-gaap:SubsegmentsAxis=cdxc:TRUNIAGENConsumerProductMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 0 | USD | 20240306 | Open filing evidence |